BACKGROUND: Despite substantial progress in the delivery of HIV prevention programs, some communities continue to experience high rates of HIV infection. We report on temporal trends in HIV prevalence in pregnant women in a community in rural KwaZulu-Natal in South Africa. METHODS: Annual, anonymous cross-sectional HIV sero-prevalence surveys were conducted between 2001 and 2013 among first visit prenatal clinic attendees. The time periods 2001 to 2003 were defined as pre-antiretroviral therapy (ART), 2004 to 2008 as early ART, and 2009 to 2013 as contemporary ART roll-out, to correspond with the substantial scale-up of ART program. RESULTS: Overall, HIV prevalence rose from 35.3% [95% confidence interval (CI): 32.3 to 38.3] pre-ART (2001-2003) to 39.0% (95% CI: 36.8 to 41.1) in the early ART (2004-2008) to 39.3% (95% CI: 37.2 to 41.4) in the contemporary ART (2009-2013) roll-out periods. In teenage women (<20 years), HIV prevalence declined from 22.5% (95% CI: 17.5 to 27.5) to 20.7% (95% CI: 17.5 to 23.8) and to 17.2% (95% CI: 14.3 to 20.2) over the similar ART roll-out periods (P = 0.046). Prevalence increased significantly in women 30 years and older (P < 0.001) over the same time period largely because of survival after ART scale up. Teenage girls with male partners of age 20-24 and ≥ 25 years had a 1.7-fold (95% CI: 1.3-2.4; P = 0.001) and 3-fold (95% CI: 2.1 to 4.3; P < 0.001) higher HIV prevalence respectively. CONCLUSIONS: Notwithstanding the encouraging decline in teenagers, the ongoing high HIV prevalence in pregnant women in this rural community, despite prevention and treatment programs, is deeply concerning. Targeted interventions for teenagers, especially for those in age-disparate relationships, are needed to impact this HIV epidemic trajectory.
BACKGROUND: Despite substantial progress in the delivery of HIV prevention programs, some communities continue to experience high rates of HIV infection. We report on temporal trends in HIV prevalence in pregnant women in a community in rural KwaZulu-Natal in South Africa. METHODS: Annual, anonymous cross-sectional HIV sero-prevalence surveys were conducted between 2001 and 2013 among first visit prenatal clinic attendees. The time periods 2001 to 2003 were defined as pre-antiretroviral therapy (ART), 2004 to 2008 as early ART, and 2009 to 2013 as contemporary ART roll-out, to correspond with the substantial scale-up of ART program. RESULTS: Overall, HIV prevalence rose from 35.3% [95% confidence interval (CI): 32.3 to 38.3] pre-ART (2001-2003) to 39.0% (95% CI: 36.8 to 41.1) in the early ART (2004-2008) to 39.3% (95% CI: 37.2 to 41.4) in the contemporary ART (2009-2013) roll-out periods. In teenage women (<20 years), HIV prevalence declined from 22.5% (95% CI: 17.5 to 27.5) to 20.7% (95% CI: 17.5 to 23.8) and to 17.2% (95% CI: 14.3 to 20.2) over the similar ART roll-out periods (P = 0.046). Prevalence increased significantly in women 30 years and older (P < 0.001) over the same time period largely because of survival after ART scale up. Teenage girls with male partners of age 20-24 and ≥ 25 years had a 1.7-fold (95% CI: 1.3-2.4; P = 0.001) and 3-fold (95% CI: 2.1 to 4.3; P < 0.001) higher HIV prevalence respectively. CONCLUSIONS: Notwithstanding the encouraging decline in teenagers, the ongoing high HIV prevalence in pregnant women in this rural community, despite prevention and treatment programs, is deeply concerning. Targeted interventions for teenagers, especially for those in age-disparate relationships, are needed to impact this HIV epidemic trajectory.
Authors: Mickey Chopra; Joy E Lawn; David Sanders; Peter Barron; Salim S Abdool Karim; Debbie Bradshaw; Rachel Jewkes; Quarraisha Abdool Karim; Alan J Flisher; Bongani M Mayosi; Stephen M Tollman; Gavin J Churchyard; Hoosen Coovadia Journal: Lancet Date: 2009-08-24 Impact factor: 79.321
Authors: Maria J Wawer; Ronald H Gray; Nelson K Sewankambo; David Serwadda; Xianbin Li; Oliver Laeyendecker; Noah Kiwanuka; Godfrey Kigozi; Mohammed Kiddugavu; Thomas Lutalo; Fred Nalugoda; Fred Wabwire-Mangen; Mary P Meehan; Thomas C Quinn Journal: J Infect Dis Date: 2005-03-30 Impact factor: 5.226
Authors: R H Gray; M J Wawer; D Serwadda; N Sewankambo; C Li; F Wabwire-Mangen; L Paxton; N Kiwanuka; G Kigozi; J Konde-Lule; T C Quinn; C A Gaydos; D McNairn Journal: Lancet Date: 1998-01-10 Impact factor: 79.321
Authors: Guy Harling; Marie-Louise Newell; Frank Tanser; Ichiro Kawachi; S V Subramanian; Till Bärnighausen Journal: J Acquir Immune Defic Syndr Date: 2014-08-01 Impact factor: 3.731
Authors: Amy A Conroy; Stacey A McKenna; Anna Leddy; Mallory O Johnson; Thulani Ngubane; Lynae A Darbes; Heidi van Rooyen Journal: AIDS Behav Date: 2017-07
Authors: Thomas Achia; Ismael Flores Cervantes; Paul Stupp; Paul Musingila; Jacques Muthusi; Anthony Waruru; Mary Schmitz; Megan Bronson; Gregory Chang; John Bore; Leonard Kingwara; Samuel Mwalili; James Muttunga; Joshua Gitonga; Kevin M De Cock; Peter Young Journal: BMC Public Health Date: 2022-07-13 Impact factor: 4.135
Authors: Nonzwakazi P Ntombela; Ayesha B M Kharsany; Adenike Soogun; Nonhlanhla Yende-Zuma; Hans-Peter Kohler; Lyle R McKinnon Journal: AIDS Behav Date: 2021-02-11
Authors: Catherine Mathews; Sander M Eggers; Loraine Townsend; Leif E Aarø; Petrus J de Vries; Amanda J Mason-Jones; Petra De Koker; Tracy McClinton Appollis; Yolisa Mtshizana; Joy Koech; Annegreet Wubs; Hein De Vries Journal: AIDS Behav Date: 2016-09